BOSTON, Mass.—October 9, 2012– Acetylon Pharmaceuticals today announced that Walter Ogier, President and CEO, will participate on the panel "The New Kids on the Biotech Block: Trends in Early Stage Financing" this morning, October 9, 2012, at 9 am PT at the BIO Investor Forum in San Francisco, CA. In addition, Mr. Ogier will give a corporate presentation at 3 pm PT, including an update of its oral histone deacetylase 6 (HDAC6) inhibitor, rocilinostat (ACY-1215), which is currently in two Phase 1b combination clinical trials with Revlimid® (lenalidomide, Celgene) and Velcade® (bortezomib, Takeda Millennium) for the treatment of relapsed and relapsed/refractory multiple myeloma.
In the panel, Mr. Ogier will discuss Acetylon's success to date in raising substantial capital for its small molecule drug development programs without resorting to venture capital funding. The Company's financing to date includes over $35M from individuals and family investment funds, $5.6M from The Leukemia and Lymphoma Society and $15M from Celgene Corporation.
About Acetylon Pharmaceuticals, Inc.
Acetylon Pharmaceuticals, Inc. is applying its unique capabilities to discover and develop next-generation, highly selective small molecule drugs to realize the therapeutic potential of HDAC inhibition to treat cancer, inflammatory and other diseases, while reducing the side effects common to this class of drugs. The Company is located in Boston and is based on technology initially developed at the Dana-Farber Cancer Institute and at Harvard University. www.acetylon.com
Revlimid® is a registered trademark of Celgene Corporation. Velcade® is a registered trademark of Millennium: the Takeda Oncology Company.
Walter C. Ogier
President and Chief Executive Officer
MacDougall Biomedical Communications